Cue Biopharma, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; balance-sheet comparisons are with December 31, 2023. Cue is a clinical-stage biopharmaceutical company developing T-cell-modulating biologics. It has no commercial product revenue and remains dependent on collaboration funding and external capital.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Collaboration revenue | $1.717 million | $0.187 million |
| Research and development expense | $10.199 million | $9.391 million |
| General and administrative expense | $4.186 million | $4.176 million |
| Operating loss | $12.668 million | $13.380 million |
| Net loss | $12.347 million; $0.25 per share | $13.109 million; $0.29 per share |
| Cash used in operations | $9.784 million | $10.833 million |
- Revenue and margins: Revenue is from collaborations, not product sales. The filing does not provide a clear gross-margin measure; operating expenses exceeded revenue by $12.668 million.
- Cash and liquidity: Cash and cash equivalents were $41.029 million at quarter-end, down from $48.514 million at year-end. Current assets were $44.669 million and current liabilities $18.090 million.
- Cash flow: Cash, cash equivalents and restricted cash declined $7.485 million during the quarter. Financing provided $2.354 million, including $3.354 million net ATM proceeds, partly offset by a $1.000 million term-loan payment.
- Debt: Term-loan principal was $7.000 million at quarter-end, with $7.207 million reported as current and long-term debt net of issuance costs and including final-payment accretion. The floating rate was 10.75%; scheduled principal maturities are $3.000 million in 2024 and $4.000 million in 2025. The loan is secured by substantially all assets other than intellectual property, which is subject to a negative pledge.
- Equity: Cue issued 1,428,200 shares through its ATM program in Q1 for $3.354 million net proceeds. Quarter-end shares outstanding were 48,643,316.
Material changes versus the prior-year quarter
- Revenue increased $1.530 million, principally because of the Ono collaboration, which generated $1.7 million of Q1 2024 revenue versus $0.2 million in Q1 2023. LG Chem revenue was $34,000 versus $36,000.
- R&D expense rose $0.8 million, mainly from higher clinical costs, partly offset by lower external manufacturing costs. G&A was essentially unchanged.
- Net loss narrowed $0.762 million. Lower operating loss and interest expense contributed; cash used in operations also fell about $1.0 million.
- Investing cash flow shifted from $15.002 million provided in Q1 2023, largely from marketable-security redemptions, to $0.055 million used in Q1 2024.
Outlook, management commentary and risks
- Runway and going concern: Management estimates existing cash will fund operations into the first quarter of 2025. The company nevertheless states that recurring losses, negative operating cash flows and a runway of less than 12 months from issuance raise substantial doubt about its ability to continue as a going concern. It expects to seek additional equity, collaborations or strategic alliances; success is not assured.
- Programs: CUE-101 and CUE-102 are in clinical development; CUE-401 and CUE-501 are earlier-stage autoimmune programs. Management reported clinical activity in CUE-101 and CUE-102 but emphasized ongoing trials and planned further data updates at the June 2024 ASCO meeting. A proposed CUE-101 Phase 2 trial was being assessed for resources and funding; it was not presented as initiated.
- Collaborations: Ono funds CUE-401 research during an option period and may later license the program, subject to its option. LG Chem holds specified territorial rights to oncology programs. Potential milestones and royalties are contingent, and the filing reports no development, regulatory or commercial milestone or royalty revenue to date.
- Key risks: Clinical and regulatory outcomes are uncertain; Cue relies on third parties for trials and manufacturing; additional capital is required and may be unavailable or dilutive; and the First Citizens loan covenants constrain financial flexibility. Management expects spending needs to increase as development proceeds.
- Other items: No material legal proceedings or contingent-liability accruals were reported. Management concluded disclosure controls were effective as of March 31, 2024, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether subsequent financing or partnering has extended the stated cash runway beyond Q1 2025, and whether the going-concern uncertainty has changed.
- Actual operating cash burn, spending plans and clinical-trial costs relative to the Q1 run rate.
- Updates on CUE-101 and CUE-102 clinical results, trial design, enrollment and regulatory discussions, including whether the proposed CUE-101 Phase 2 trial proceeds.
- Ono option timing, research funding and any decision to exercise its CUE-401 license option; also verify the timing and amount of any collaboration revenue or milestone payments.
- Debt repayment schedule, 10.75% floating interest rate, covenant compliance and cash restrictions under the loan agreement.
- Share dilution and warrant overhang: the filing reports 9,188,406 warrants and 1,531,440 pre-funded warrants outstanding. Weighted-average shares used for Q1 loss per share were 49,466,711, including pre-funded warrants, versus 48,643,316 issued and outstanding at quarter-end.